These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38677148)

  • 41. Medication utilization for patients with chronic rhinosinusitis with nasal polyposis and asthma in 12 months pre- and post-dupilumab initiation.
    Garvey E; Naimi B; Duffy A; Kahn C; Farquhar D; Rosen M; Rabinowitz M; Evertz DP; Most J; Toskala E; Nyquist GG
    Int Forum Allergy Rhinol; 2024 Aug; 14(8):1399-1401. PubMed ID: 38409897
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dupilumab's impact on nasal citology: Real life experience after 1 year of treatment.
    Gelardi M; Giancaspro R; Quaranta VN; La Gatta E; Ruzza A; Cassano M
    Am J Otolaryngol; 2024; 45(4):104275. PubMed ID: 38574514
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness and safety profile of mepolizumab in chronic rhinosinusitis with nasal polyps: Real life data in a tertiary care.
    Galletti C; Ciodaro F; Barbieri MA; Gambino F; Ferrisi MG; Portelli D; Catalano N; Spina E; Freni F; Galletti B
    Am J Otolaryngol; 2024; 45(4):104329. PubMed ID: 38696895
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Very Rapid Improvement in Extended Nitric Oxide Parameters Is Associated With Clinical and Functional Improvement in Patients With Chronic Rhinosinusitis With Nasal Polyps Treated With Dupilumab.
    Paoletti G; Casini M; Malvezzi L; Pirola F; Russo E; Nappi E; Muci GQ; Montagna C; Messina MR; Ferri S; Racca F; Lamacchia D; Cataldo G; Puggioni F; De Virgilio A; Ferreli F; Mercante G; Spriano G; Canonica GW; Heffler E
    J Investig Allergol Clin Immunol; 2023 Dec; 33(6):457-463. PubMed ID: 38095494
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52.
    Bachert C; Khan AH; Lee SE; Hopkins C; Peters AT; Fokkens W; Praestgaard A; Radwan A; Nash S; Jacob-Nara JA; Deniz Y; Rowe PJ
    Int Forum Allergy Rhinol; 2024 Mar; 14(3):668-678. PubMed ID: 37548085
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis.
    Miglani A; Soler ZM; Smith TL; Mace JC; Schlosser RJ
    Int Forum Allergy Rhinol; 2023 Feb; 13(2):116-128. PubMed ID: 35980852
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential nasal swab cytology represents a valuable tool for therapy monitoring but not prediction of therapy response in chronic rhinosinusitis with nasal polyps treated with Dupilumab.
    Danisman Z; Linxweiler M; Kühn JP; Linxweiler B; Solomayer EF; Wagner M; Wagenpfeil G; Schick B; Berndt S
    Front Immunol; 2023; 14():1127576. PubMed ID: 37180133
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.
    Mullol J; Laidlaw TM; Bachert C; Mannent LP; Canonica GW; Han JK; Maspero JF; Picado C; Daizadeh N; Ortiz B; Li Y; Ruddy M; Laws E; Amin N
    Allergy; 2022 Apr; 77(4):1231-1244. PubMed ID: 34459002
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds.
    Chuang CC; Guillemin I; Bachert C; Lee SE; Hellings PW; Fokkens WJ; Duverger N; Fan C; Daizadeh N; Amin N; Mannent LP; Khan AH; Kamat S
    Laryngoscope; 2022 Feb; 132(2):259-264. PubMed ID: 34817082
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status.
    Fujieda S; Matsune S; Takeno S; Ohta N; Asako M; Bachert C; Inoue T; Takahashi Y; Fujita H; Deniz Y; Rowe P; Ortiz B; Li Y; Mannent LP
    Allergy; 2022 Jan; 77(1):186-196. PubMed ID: 33993501
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sleep quality improves with endoscopic sinus surgery in patients with chronic rhinosinusitis and nasal polyposis.
    Värendh M; Johannisson A; Hrubos-Strøm H; Andersson M
    Rhinology; 2017 Mar; 55(1):45-52. PubMed ID: 28019643
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis.
    Peters AT; Wagenmann M; Bernstein JA; Khan AH; Nash S; Jacob-Nara JA; Siddiqui S; Rowe PJ; Deniz Y
    Allergy Asthma Proc; 2023 Jul; 44(4):265-274. PubMed ID: 37480206
    [No Abstract]   [Full Text] [Related]  

  • 53. Doxycycline may be more clinically effective in type 2 chronic rhinosinusitis nasal polyp comorbid with asthma.
    Paçacı Çetin G; Arslan B; Yılmaz İ
    J Asthma; 2024 Jan; 61(1):20-26. PubMed ID: 37437223
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study.
    Fokkens W; Trigg A; Lee SE; Chan RH; Diamant Z; Hopkins C; Howarth P; Lund V; Mayer B; Sousa AR; Yancey S; Tabberer M;
    J Patient Rep Outcomes; 2023 Jan; 7(1):4. PubMed ID: 36662344
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dupilumab in pediatric severe chronic rhinosinusitis with nasal polyps and asthma.
    Bragança M; Pereira AM; Plácido JL; Amaral L
    Eur Ann Otorhinolaryngol Head Neck Dis; 2024 Jan; 141(1):55-56. PubMed ID: 37591762
    [No Abstract]   [Full Text] [Related]  

  • 56. Global influence of dupilumab on Quality of Life in a severe asthma patient with T2 multimorbidities: a case report on atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.
    Colque-Bayona M; Hernández-Cano N; Tomás-Pérez M; Caballero T; Quirce S; Domínguez-Ortega J
    J Asthma; 2024 Jul; 61(7):762-765. PubMed ID: 38152869
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dupilumab in chronic rhinosinusitis with nasal polyposis: current status, challenges, and future perspectives.
    Li T; Yin J; Yang Y; Wang G; Zhang Y; Song X
    Expert Rev Clin Immunol; 2023; 19(8):939-948. PubMed ID: 37378551
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Obstructive sleep apnea in patients with chronic rhinosinusitis with nasal polyps: a cross-sectional study.
    Migueis DP; Lacerda GCB; Lopes MC; Azevedo-Soster LMSF; Thuler LCS; Lemes LNA; Araujo-Melo MH
    Sleep Med; 2019 Dec; 64():43-47. PubMed ID: 31655325
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Severe chronic rhinosinusitis treated with dupilumab, a real-life analysis of early effectiveness.
    Mocellin D; Ioppi A; Gaglio G; Pennacchi A; Bertolini M; Tirrito A; Guastini L; Bagnasco D; Passalacqua G; Peretti G; Canevari FRM
    Eur Rev Med Pharmacol Sci; 2023 Aug; 27(15):7324-7336. PubMed ID: 37606141
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Real-World Adverse Events After Type 2 Biologic use in Chronic Rhinosinusitis with Nasal Polyps.
    Dorling M; Hernaiz-Leonardo JC; Pascual A; Janjua A; Thamboo A; Javer A
    Laryngoscope; 2024 Jul; 134(7):3054-3059. PubMed ID: 38314858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.